Hepatocellular carcinoma: Prevention and therapy

Current Oncology Reports

Volumn 13, Issue 3, 2011, Pages 186-194

  Sohal, Davendra P S ^a   Sun, Weijing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ablation; Chemotherapy; Cirrhosis; Hepatitis B virus (HBV); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Nonalcoholic steatohepatitis (NASH); Prevention; Resection; Sorafenib; Transarterial chemoembolization (TACE); Transplantation; Vaccine

Indexed keywords

ALCOHOL; ALPHA2B INTERFERON; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CISPLATIN; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; IODINATED POPPYSEED OIL; IODINE 131; LOW MOLECULAR WEIGHT HEPARIN; MAPATUMUMAB; MITOMYCIN C; OXALIPLATIN; PLACEBO; SORAFENIB; YTTRIUM 90;

ALCOHOL LIVER CIRRHOSIS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; AUTOIMMUNE DISEASE; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; INOPERABLE CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; METASTASIS; NONALCOHOLIC FATTY LIVER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOFREQUENCY ABLATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MICROSPHERES; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79955912643     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-011-0165-0     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
2. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-35. (Pubitemid 41831904)
3. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:191-207. x-xi.
4. Kudo M. Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. Oncology;78 Suppl 1:1-6.
5. Plymoth A, Viviani S, Hainaut P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett. 2009;286:15-21.
6. Chang MH, Shau WY, Chen CJ, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284:3040-2.
7. Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat;17:435-43.
8. Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med. 2009;76 Suppl 3:S6-9.
9. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16:75-90.
10. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124-30. (Pubitemid 29168746)
11. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97-S103. (Pubitemid 39423375)
12. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127:S79-86.
13. Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am. 2005;89:391-409. (Pubitemid 40126823)
14. AASLD Practice Guideline. Management of Hepatocellular Carcinoma: An Update. American Association for the Study of Liver Diseases., 2010. (Accessed October 31, 2010. at http://www.aasld.org/practiceguidelines/Documents/ Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf.). Updated guidelines on HCC management, by the American Association for Study of Liver Diseases.
15. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-22.
16. Ribero D, Curley SA, Imamura H, et al. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol. 2008;15:986-92.
17. Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol;21 Suppl 5:v59-64. Updated guidelines on HCC management, by the European Society for Medical Oncology.
18. Jaeck D, Bachellier P, Oussoultzoglou E, Weber JC, Wolf P. Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview. Liver Transpl. 2004;10:S58-63.
19. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-40.
20. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9. (Pubitemid 26079803)
21. Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009;9:31. Meta-analysis showing that RFA is better than ethanol injection as local therapy for HCC; although individual studies are somewhat heterogeneous, better survival was seen with RFA.
22. Lencioni R, Bartolozzi C, Caramella D, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer. 1995;76:1737-46.
23. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-42. (Pubitemid 36152543)
24. ZhouWP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009;249:195-202.
25. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-8.
26. Yao FY, Kerlan Jr RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819-27.
27. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol;33:41-52.
28. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology;52:762-73.
29. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81. (Pubitemid 351171043)
30. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology; 138:52-64.
31. Benson AB, 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350-91. Updated guidelines on HCC management, by the National Comprehensive Cancer Network. Chemotherapy is not recommended outside of a clinical trial.
32. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother;11:1943-55.
33. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. This is the landmark randomized controlled trial of sorafenib versus placebo, showing an improvement in overall survival with sorafenib in advanced HCC.
34. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. This is the second randomized controlled trial of sorafenib versus placebo showing an improvement in overall survival with sorafenib in advanced HCC. Conducted in a different geographic area, results were not as striking as in the SHARP trial, however.
35. Cantarini MC, Trevisani F, Morselli-Labate AM, et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:91-8. (Pubitemid 43381714)
36. Trevisani F, Magini G, Santi V, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007;102:1022-31. (Pubitemid 46698223)
37. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532-8. (Pubitemid 41631953)
38. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109:1384-90. (Pubitemid 46466566)
39. Qin S, Bai, Y., Ye, S., et al. Phase III study of oxaliplatin plus 5- fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol 2010;28:abstr 4008. Interesting preliminary results were seen in this randomized controlled trial: an improvement in overall survival with combination chemotherapy for advanced HCC. Final results are eagerly awaited.
40. Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer. 2007;97:862-7. (Pubitemid 47519302)
41. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008;112:2733-9. (Pubitemid 351969218)
42. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898-903. (Pubitemid 46638989)
43. Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102:981-6.
44. Sun W, Sohal D, Haller D, et al. Phase II Trial of Bevacizumab, Capecitabine and Oxaliplatin in Treatment of Advanced Hepatocellular Carcinoma. CA Cancer J Clin 2010.
45. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27:843-50.
46. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma: A Randomized Trial. JAMA. 2010;304:2154-60.
47. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol;28:3994-4005. This report highlights the current practice standards for HCC treatment and outlines the major research questions that need to be answered, along with information on ongoing clinical trials that are addressing some of these questions.
48. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg. 1998;133:183-8. (Pubitemid 28092919)
49. Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44:891-5. (Pubitemid 46489553)
50. Soderdahl G, Backman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int. 2006;19:288-94.